Posts Tagged ‘5AR2 monotherapy with finasteride alone’

URO TODAY: Enzymes in the prostate that promote aggressive cancer growth need to be suppressed and a study looks at the success of new drugs now available to do the job. READ MORE>

The objective of this review is to provide an understanding of the pharmacological properties and the potential clinical benefits of 5AR inhibition.

The efficacy of 5AR2 monotherapy with finasteride alone or in combination with an androgen receptor antagonist on more final outcome measures seems to be limited.

Combining an androgen receptor antagonist with a 5AR inhibitor in patients with asymptomatic, locally advanced or recurrent prostate cancer might be a reasonable first therapeutic hormonal approach.

5-alpha reductase is an enzyme that converts testosterone, the male sex hormone, into the more potent dihydrotestosterone:

Read Full Post »